| Popis: |
Rubens Camargo Siqueira1,2 1Department of Retina, Rubens Siqueira Research Center, São José do Rio Preto, São Paulo, Brazil; 2Postgraduate Department, Faculty of Medicine of São José do Rio Preto (FAMERP), São José do Rio Preto, São Paulo, BrazilCorrespondence: Rubens Camargo Siqueira, Email siqueiraretina@gmail.comAbstract: Photobiomodulation (PBM) is a type of phototherapy that employs light-emitting diodes (LEDs) or low-power lasers to selectively administer specific wavelengths of visible light, ranging from 500 to 1000 nm, including near-infrared (NIR) wavelengths. LEDs are advantageous compared to lasers due to their ability to treat large areas at a lower cost, lack of tissue damage potential in humans, and reduced risk of eye-related accidents. The ophthalmology community has recently taken interest in PBM as a promising novel approach for managing various retinal conditions such as age-related macular degeneration, retinopathy of prematurity, retinitis pigmentosa, diabetic retinopathy, Leber’s hereditary optic neuropathy, amblyopia, methanol-induced retinal damage, and potentially others. This review critically assesses the existing body of research on PBM applications in the retina, focusing on elucidating the underlying mechanisms of action and evaluating the clinical outcomes associated with this therapeutic modality.Keywords: photobiomodulation, near-infrared, light emitting diode, age-related macular degeneration |
